Allstate Corp Invests $560,000 in The Clorox Company $CLX

Allstate Corp acquired a new stake in The Clorox Company (NYSE:CLX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,538 shares of the company’s stock, valued at approximately $560,000.

Several other institutional investors have also recently added to or reduced their stakes in CLX. Brown Lisle Cummings Inc. raised its holdings in Clorox by 4.3% during the second quarter. Brown Lisle Cummings Inc. now owns 2,136 shares of the company’s stock worth $256,000 after purchasing an additional 89 shares in the last quarter. American National Bank & Trust grew its position in shares of Clorox by 69.5% in the 2nd quarter. American National Bank & Trust now owns 217 shares of the company’s stock valued at $26,000 after buying an additional 89 shares during the last quarter. Savvy Advisors Inc. raised its stake in Clorox by 1.4% during the 2nd quarter. Savvy Advisors Inc. now owns 6,395 shares of the company’s stock worth $768,000 after acquiring an additional 91 shares in the last quarter. Canandaigua National Bank & Trust Co. lifted its position in Clorox by 0.8% in the third quarter. Canandaigua National Bank & Trust Co. now owns 11,196 shares of the company’s stock valued at $1,380,000 after acquiring an additional 94 shares during the last quarter. Finally, State of Michigan Retirement System boosted its stake in Clorox by 0.3% in the second quarter. State of Michigan Retirement System now owns 33,551 shares of the company’s stock valued at $4,028,000 after acquiring an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Stock Up 1.5%

CLX stock opened at $112.18 on Friday. The company has a current ratio of 0.76, a quick ratio of 0.50 and a debt-to-equity ratio of 18.01. The company’s 50-day moving average price is $103.60 and its 200 day moving average price is $114.94. The Clorox Company has a 52 week low of $96.66 and a 52 week high of $164.22. The company has a market cap of $13.68 billion, a P/E ratio of 17.61, a P/E/G ratio of 0.55 and a beta of 0.58.

Clorox (NYSE:CLX) last issued its earnings results on Monday, November 3rd. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.07. The company had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.41 billion. Clorox had a net margin of 11.68% and a return on equity of 358.39%. The firm’s quarterly revenue was down 18.9% compared to the same quarter last year. During the same period last year, the company posted $1.86 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. On average, research analysts expect that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Wednesday, January 28th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Wednesday, January 28th. This represents a $4.96 annualized dividend and a yield of 4.4%. Clorox’s payout ratio is currently 77.86%.

Key Stories Impacting Clorox

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Clorox announced a definitive all‑cash deal to buy GOJO (Purell maker) for $2.25 billion (roughly $1.92B net after ~$330M tax benefits). Management says the deal expands Clorox’s health & hygiene scale, adds a large B2B business (hospitals, professional channels), and is growth-accretive and aligned with its IGNITE strategy — a clear near-term catalyst for revenue diversification and margin improvement. Clorox Announces Acquisition of GOJO
• Positive Sentiment: Clorox raised its FY‑2026 EPS guidance to $5.95–$6.30 (consensus ~$5.91) and issued revenue guidance of $6.4–$6.7B (consensus ~$6.5B). The EPS range topping consensus and a revenue range that includes street expectations provide a modest positive signal on near-term profitability expectations.
• Neutral Sentiment: A personal‑finance feature compared tobacco giant Altria to alternative high‑yield dividend growth options; while not focused on CLX, such coverage can shift investor attention toward dividend‑stable consumer names. Should You Forget Altria?
• Negative Sentiment: Barclays reiterated an Underweight/​sell stance on CLX despite nudging its price target to $109, signaling persistent analyst concerns about Clorox’s fundamentals and secular pressures across categories. Such continued negative analyst bias could limit near‑term upside even after the acquisition news. Barclays Raises CLX Target to $109 but Keeps Underweight
• Negative Sentiment: Analyst previews note private‑label and category share pressure (e.g., retailers’ own brands), which can compress volume and pricing power in core household categories — a structural headwind that could temper the benefit from the GOJO deal. Clorox Q2 Preview: Private Label Pressure Clouds The Outlook

Insider Buying and Selling

In other news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction on Friday, November 21st. The shares were bought at an average price of $104.13 per share, with a total value of $416,520.00. Following the completion of the acquisition, the director owned 13,000 shares of the company’s stock, valued at approximately $1,353,690. This trade represents a 44.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.63% of the company’s stock.

Analysts Set New Price Targets

CLX has been the subject of several research reports. Wells Fargo & Company reduced their target price on Clorox from $117.00 to $108.00 and set an “equal weight” rating for the company in a report on Monday, January 5th. Citigroup cut their price target on Clorox from $120.00 to $109.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 17th. Deutsche Bank Aktiengesellschaft decreased their price objective on Clorox from $128.00 to $121.00 and set a “hold” rating for the company in a report on Tuesday, November 4th. The Goldman Sachs Group cut their target price on shares of Clorox from $110.00 to $94.00 and set a “sell” rating on the stock in a report on Wednesday, January 7th. Finally, Zacks Research upgraded shares of Clorox from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. One investment analyst has rated the stock with a Buy rating, thirteen have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Clorox currently has an average rating of “Reduce” and an average target price of $122.19.

Clorox Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.